Saori Abe
@oriabe114.bsky.social
Rheumatologist🇯🇵MD, PhD👩⚕️mom 👦👧
📖Sjogren’s, Lupus, APS, reproductive health, translational research❤︎
📖Sjogren’s, Lupus, APS, reproductive health, translational research❤︎
Reposted by Saori Abe
Review: Pathogenic drivers of lupus myocarditis and potential therapeutic targets @taejoonw.bsky.social
www.nature.com/articles/s12...
www.nature.com/articles/s12...
November 9, 2025 at 10:34 PM
Review: Pathogenic drivers of lupus myocarditis and potential therapeutic targets @taejoonw.bsky.social
www.nature.com/articles/s12...
www.nature.com/articles/s12...
Reposted by Saori Abe
@natrevrheum.nature.com Cutaneous lupus erythematosus — from pathogenesis to targeted therapy @kahlenberglab.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Cutaneous lupus erythematosus — from pathogenesis to targeted therapy - Nature Reviews Rheumatology
This Review discusses latest advances in the field of cutaneous lupus, including the improved understanding of disease pathogenesis and emerging targeted therapies.
www.nature.com
November 9, 2025 at 10:35 PM
@natrevrheum.nature.com Cutaneous lupus erythematosus — from pathogenesis to targeted therapy @kahlenberglab.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
www.science.org/doi/10.1126/...
📖”Through a lineage-tracing approach, they detected conversion of synovial TH17 cells to CD44+ IFN-γ−IL-10− exTH17 cells, which are arthritogenic and cause joint inflammation independent of IL-17. “
#Th17 #arthritis
📖”Through a lineage-tracing approach, they detected conversion of synovial TH17 cells to CD44+ IFN-γ−IL-10− exTH17 cells, which are arthritogenic and cause joint inflammation independent of IL-17. “
#Th17 #arthritis
TH17 cells converted into exTH17 cells sustain rheumatoid-like IL-17–independent inflammatory arthritis
ExTH17 cells drive IL-17–independent chronic SKG arthritis in mice through up-regulation of CD44 and S1PR4 and cross-talk with FLS.
www.science.org
November 8, 2025 at 10:59 PM
www.science.org/doi/10.1126/...
📖”Through a lineage-tracing approach, they detected conversion of synovial TH17 cells to CD44+ IFN-γ−IL-10− exTH17 cells, which are arthritogenic and cause joint inflammation independent of IL-17. “
#Th17 #arthritis
📖”Through a lineage-tracing approach, they detected conversion of synovial TH17 cells to CD44+ IFN-γ−IL-10− exTH17 cells, which are arthritogenic and cause joint inflammation independent of IL-17. “
#Th17 #arthritis
www.cell.com/immunity/abs...
📖 Highly functional and prolonged germinal center T follicular helper cell responses are associated with enhanced neutralizing antibody development
#Tfh #germinalcenter
📖 Highly functional and prolonged germinal center T follicular helper cell responses are associated with enhanced neutralizing antibody development
#Tfh #germinalcenter
Highly functional and prolonged germinal center T follicular helper cell responses are associated with enhanced neutralizing antibody development
The dynamics of antigen-specific Tfh responses during extended germinal center reactions
are not well characterized. Marina-Zárate et al. show that vaccine-specific Tfh cells
in the lymph node undergo...
www.cell.com
November 8, 2025 at 10:51 PM
www.cell.com/immunity/abs...
📖 Highly functional and prolonged germinal center T follicular helper cell responses are associated with enhanced neutralizing antibody development
#Tfh #germinalcenter
📖 Highly functional and prolonged germinal center T follicular helper cell responses are associated with enhanced neutralizing antibody development
#Tfh #germinalcenter
Reposted by Saori Abe
TLR7 drives age-associated B cell formation in lupus through m6A demethylase FTO-mediated mitochondrial oxidation
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
November 6, 2025 at 1:41 AM
TLR7 drives age-associated B cell formation in lupus through m6A demethylase FTO-mediated mitochondrial oxidation
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Reposted by Saori Abe
🆕 Clinical Year in Review at #ACR25
By Dr. Bryant England @unmc.bsky.social
🔶 Review the most impactful studies in #Rheumatology from the past year!
❓ Any studies you would add to the list?
#RheumSky #MedSky #YearInReview
By Dr. Bryant England @unmc.bsky.social
🔶 Review the most impactful studies in #Rheumatology from the past year!
❓ Any studies you would add to the list?
#RheumSky #MedSky #YearInReview
October 29, 2025 at 6:00 PM
🆕 Clinical Year in Review at #ACR25
By Dr. Bryant England @unmc.bsky.social
🔶 Review the most impactful studies in #Rheumatology from the past year!
❓ Any studies you would add to the list?
#RheumSky #MedSky #YearInReview
By Dr. Bryant England @unmc.bsky.social
🔶 Review the most impactful studies in #Rheumatology from the past year!
❓ Any studies you would add to the list?
#RheumSky #MedSky #YearInReview
Reposted by Saori Abe
🆕 2025 ACR Guideline for Treatment of Systemic #Lupus Erythematosus 🦋
Just Released: Nov 3 #ACR25 🔥
🔸Review organ-specific treatment recommendations
🔸Steroid & HCQ Use Guidance
🔸Management of Comorbidities
➠ Read the Full Guideline here: acr.tw/47mkegj
#RheumSky #SLE #Rheumatology
Just Released: Nov 3 #ACR25 🔥
🔸Review organ-specific treatment recommendations
🔸Steroid & HCQ Use Guidance
🔸Management of Comorbidities
➠ Read the Full Guideline here: acr.tw/47mkegj
#RheumSky #SLE #Rheumatology
November 5, 2025 at 6:28 PM
🆕 2025 ACR Guideline for Treatment of Systemic #Lupus Erythematosus 🦋
Just Released: Nov 3 #ACR25 🔥
🔸Review organ-specific treatment recommendations
🔸Steroid & HCQ Use Guidance
🔸Management of Comorbidities
➠ Read the Full Guideline here: acr.tw/47mkegj
#RheumSky #SLE #Rheumatology
Just Released: Nov 3 #ACR25 🔥
🔸Review organ-specific treatment recommendations
🔸Steroid & HCQ Use Guidance
🔸Management of Comorbidities
➠ Read the Full Guideline here: acr.tw/47mkegj
#RheumSky #SLE #Rheumatology
Reposted by Saori Abe
S-TIR-ring up TLR7 and TLR9: signaling domain substitutions clarify the TLR paradox
www.jci.org/articles/vie...
@jci.org
www.jci.org/articles/vie...
www.jci.org/articles/vie...
@jci.org
www.jci.org/articles/vie...
November 4, 2025 at 10:38 PM
S-TIR-ring up TLR7 and TLR9: signaling domain substitutions clarify the TLR paradox
www.jci.org/articles/vie...
@jci.org
www.jci.org/articles/vie...
www.jci.org/articles/vie...
@jci.org
www.jci.org/articles/vie...
Reposted by Saori Abe
Now published: The 2025 ACR Guideline for the Treatment of Systemic Lupus Erythematosus
📄 Read the paper: acr.tw/47mkegj
ℹ️ See additional content and resources on this guideline at acr.tw/4mbHK4W
#Medsky #Rheumsky #Rheumatology
📄 Read the paper: acr.tw/47mkegj
ℹ️ See additional content and resources on this guideline at acr.tw/4mbHK4W
#Medsky #Rheumsky #Rheumatology
November 3, 2025 at 4:35 PM
Now published: The 2025 ACR Guideline for the Treatment of Systemic Lupus Erythematosus
📄 Read the paper: acr.tw/47mkegj
ℹ️ See additional content and resources on this guideline at acr.tw/4mbHK4W
#Medsky #Rheumsky #Rheumatology
📄 Read the paper: acr.tw/47mkegj
ℹ️ See additional content and resources on this guideline at acr.tw/4mbHK4W
#Medsky #Rheumsky #Rheumatology
www.thelancet.com/journals/lan...
👉”Fc receptor blockade by nipocalimab 15 mg/kg significantly improved clinical disease activity versus placebo and was safe and well tolerated in participants with moderate-to-severe, active Sjögren's disease.”
#Sjogren #PhaseII
👉”Fc receptor blockade by nipocalimab 15 mg/kg significantly improved clinical disease activity versus placebo and was safe and well tolerated in participants with moderate-to-severe, active Sjögren's disease.”
#Sjogren #PhaseII
Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial
Fc receptor blockade by nipocalimab 15 mg/kg significantly improved clinical disease
activity versus placebo and was safe and well tolerated in participants with moderate-to-severe,
active Sjögren's d...
www.thelancet.com
November 1, 2025 at 9:57 PM
www.thelancet.com/journals/lan...
👉”Fc receptor blockade by nipocalimab 15 mg/kg significantly improved clinical disease activity versus placebo and was safe and well tolerated in participants with moderate-to-severe, active Sjögren's disease.”
#Sjogren #PhaseII
👉”Fc receptor blockade by nipocalimab 15 mg/kg significantly improved clinical disease activity versus placebo and was safe and well tolerated in participants with moderate-to-severe, active Sjögren's disease.”
#Sjogren #PhaseII
www.sciencedirect.com/science/arti...
📖 GZMK+CD8+ T cells target a specific acinar cell type in Sjögren's disease
#Sjogren #Tcell
📖 GZMK+CD8+ T cells target a specific acinar cell type in Sjögren's disease
#Sjogren #Tcell
GZMK+CD8+ T cells target a specific acinar cell type in Sjögren's disease
Sjögren's disease (SjD) is a systemic autoimmune disorder characterized by dysfunction of exocrine glands, particularly the salivary and lacrimal glan…
www.sciencedirect.com
November 1, 2025 at 2:00 PM
www.sciencedirect.com/science/arti...
📖 GZMK+CD8+ T cells target a specific acinar cell type in Sjögren's disease
#Sjogren #Tcell
📖 GZMK+CD8+ T cells target a specific acinar cell type in Sjögren's disease
#Sjogren #Tcell
www.nature.com/articles/s41...
📖 “The exonuclease PLD4 helps restrain activation of TLR7 and TLR9 by cleaving their ligands.
…identified loss-of-function variants in PLD4 in five patients with #SLE, linking disruption of this regulatory mechanism with systemic inflammation and #autoimmunity.”
📖 “The exonuclease PLD4 helps restrain activation of TLR7 and TLR9 by cleaving their ligands.
…identified loss-of-function variants in PLD4 in five patients with #SLE, linking disruption of this regulatory mechanism with systemic inflammation and #autoimmunity.”
PLD4 variants promote SLE via unchecked TLR activation - Nature Reviews Rheumatology
Biallelic loss-of-function mutations in PLD4, as identified in five patients with SLE, lead to Toll-like receptor-driven hyperactivation of type I interferon, immune cell expansion and autoimmunity.
www.nature.com
November 1, 2025 at 1:54 PM
www.nature.com/articles/s41...
📖 “The exonuclease PLD4 helps restrain activation of TLR7 and TLR9 by cleaving their ligands.
…identified loss-of-function variants in PLD4 in five patients with #SLE, linking disruption of this regulatory mechanism with systemic inflammation and #autoimmunity.”
📖 “The exonuclease PLD4 helps restrain activation of TLR7 and TLR9 by cleaving their ligands.
…identified loss-of-function variants in PLD4 in five patients with #SLE, linking disruption of this regulatory mechanism with systemic inflammation and #autoimmunity.”
www.nature.com/articles/s41...
📖”Telitacicept, a dual inhibitor of BAFF and APRIL, has now been shown in a phase III randomized controlled trial to improve systemic lupus erythematosus (SLE) disease activity when added to standard therapy.”
#SLE #lupus #phaseIII
📖”Telitacicept, a dual inhibitor of BAFF and APRIL, has now been shown in a phase III randomized controlled trial to improve systemic lupus erythematosus (SLE) disease activity when added to standard therapy.”
#SLE #lupus #phaseIII
Phase III trial of telitacicept in SLE - Nature Reviews Rheumatology
In a phase III placebo-controlled trial, the addition of telitacicept to standard therapy led to increased clinical response rates for people with systemic lupus erythematosus.
www.nature.com
November 1, 2025 at 1:49 PM
www.nature.com/articles/s41...
📖”Telitacicept, a dual inhibitor of BAFF and APRIL, has now been shown in a phase III randomized controlled trial to improve systemic lupus erythematosus (SLE) disease activity when added to standard therapy.”
#SLE #lupus #phaseIII
📖”Telitacicept, a dual inhibitor of BAFF and APRIL, has now been shown in a phase III randomized controlled trial to improve systemic lupus erythematosus (SLE) disease activity when added to standard therapy.”
#SLE #lupus #phaseIII
Reposted by Saori Abe
October 25, 2025 at 6:24 PM
Reposted by Saori Abe
October 26, 2025 at 2:56 PM
Reposted by Saori Abe
IMPORTANT ANNOUCEMENT❗️ YOU CAN SNUGGLE PUPPIES IN THE RELAXATION AREA!!! Also, they will be adoptable very soon if you’re in the market for a new best friend! #ACR25 #chooserheum #Rheumatology
October 26, 2025 at 8:02 PM
IMPORTANT ANNOUCEMENT❗️ YOU CAN SNUGGLE PUPPIES IN THE RELAXATION AREA!!! Also, they will be adoptable very soon if you’re in the market for a new best friend! #ACR25 #chooserheum #Rheumatology
Reposted by Saori Abe
New recipe improves creation of cells that could fight most autoimmune diseases @science.org
Nobel laureate makes regulatory T cells that last longer in the body, boosting clinical hopes
www.science.org/content/arti...
Nobel laureate makes regulatory T cells that last longer in the body, boosting clinical hopes
www.science.org/content/arti...
New recipe improves creation of cells that could fight most autoimmune diseases
Nobel laureate makes regulatory T cells that last longer in the body, boosting clinical hopes
www.science.org
October 23, 2025 at 6:40 PM
New recipe improves creation of cells that could fight most autoimmune diseases @science.org
Nobel laureate makes regulatory T cells that last longer in the body, boosting clinical hopes
www.science.org/content/arti...
Nobel laureate makes regulatory T cells that last longer in the body, boosting clinical hopes
www.science.org/content/arti...
www.nature.com/articles/s41...
“Single-cell transcriptomic analysis of blood CD4+ T cells from children with systemic lupus erythematosus (SLE) reveals an unexpected diversity of helper and regulatory cells that could underlie disease flares and organ damage.”
#SLE #lupus #Tcell
“Single-cell transcriptomic analysis of blood CD4+ T cells from children with systemic lupus erythematosus (SLE) reveals an unexpected diversity of helper and regulatory cells that could underlie disease flares and organ damage.”
#SLE #lupus #Tcell
Charting new territory for T cells in pediatric lupus - Nature Immunology
Single-cell transcriptomic analysis of blood CD4+ T cells from children with systemic lupus erythematosus (SLE) reveals an unexpected diversity of helper and regulatory cells that could underlie disea...
www.nature.com
October 24, 2025 at 2:07 PM
www.nature.com/articles/s41...
“Single-cell transcriptomic analysis of blood CD4+ T cells from children with systemic lupus erythematosus (SLE) reveals an unexpected diversity of helper and regulatory cells that could underlie disease flares and organ damage.”
#SLE #lupus #Tcell
“Single-cell transcriptomic analysis of blood CD4+ T cells from children with systemic lupus erythematosus (SLE) reveals an unexpected diversity of helper and regulatory cells that could underlie disease flares and organ damage.”
#SLE #lupus #Tcell
www.nature.com/articles/s41...
“we observed an expansion of dysfunctional #Treg in pts with #lupusnephritis, along with↑ of TLR5 and FCRL3 in naive Treg… These findings highlight distinct CD4⁺ T cell subsets that may contribute to aberrant antibody responses and impaired immune regulation in #SLE.”
“we observed an expansion of dysfunctional #Treg in pts with #lupusnephritis, along with↑ of TLR5 and FCRL3 in naive Treg… These findings highlight distinct CD4⁺ T cell subsets that may contribute to aberrant antibody responses and impaired immune regulation in #SLE.”
Single-cell RNA profiling of blood CD4+ T cells identifies distinct helper and dysfunctional regulatory clusters in children with SLE - Nature Immunology
Caielli and colleagues performed single-cell RNA sequencing on blood CD4⁺ T cells from pediatric patients with systemic lupus erythematosus and healthy donors, identifying naive, memory, Treg, prolife...
www.nature.com
October 24, 2025 at 2:01 PM
www.nature.com/articles/s41...
“we observed an expansion of dysfunctional #Treg in pts with #lupusnephritis, along with↑ of TLR5 and FCRL3 in naive Treg… These findings highlight distinct CD4⁺ T cell subsets that may contribute to aberrant antibody responses and impaired immune regulation in #SLE.”
“we observed an expansion of dysfunctional #Treg in pts with #lupusnephritis, along with↑ of TLR5 and FCRL3 in naive Treg… These findings highlight distinct CD4⁺ T cell subsets that may contribute to aberrant antibody responses and impaired immune regulation in #SLE.”
www.nature.com/articles/s41...
📖Research Briefing
Glomerular cross-talk in the progression of autoimmune kidney disease
#ANCA #SLE #nephritis
📖Research Briefing
Glomerular cross-talk in the progression of autoimmune kidney disease
#ANCA #SLE #nephritis
Glomerular cross-talk in the progression of autoimmune kidney disease - Nature Immunology
Rapidly progressive glomerulonephritis refers to a group of severe autoimmune kidney diseases. Using high-resolution spatial transcriptomics, we identified a common pathway of disease progression and ...
www.nature.com
October 21, 2025 at 12:37 AM
www.nature.com/articles/s41...
📖Research Briefing
Glomerular cross-talk in the progression of autoimmune kidney disease
#ANCA #SLE #nephritis
📖Research Briefing
Glomerular cross-talk in the progression of autoimmune kidney disease
#ANCA #SLE #nephritis
Reposted by Saori Abe
BREAKING NEWS: The FDA has approved Gazyva® (obinutuzumab) for the treatment of adults with #lupus nephritis. Gazyva is the fourth therapy for lupus to receive regulatory approval since 2011.
Read the announcement: buff.ly/81tYgo7
Read the announcement: buff.ly/81tYgo7
October 20, 2025 at 1:02 PM
BREAKING NEWS: The FDA has approved Gazyva® (obinutuzumab) for the treatment of adults with #lupus nephritis. Gazyva is the fourth therapy for lupus to receive regulatory approval since 2011.
Read the announcement: buff.ly/81tYgo7
Read the announcement: buff.ly/81tYgo7
Reposted by Saori Abe
Efficacy of Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL, in adults with active systemic lupus erythematosus @nejm.org
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
October 17, 2025 at 1:37 AM
Efficacy of Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL, in adults with active systemic lupus erythematosus @nejm.org
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Reposted by Saori Abe
#ACR25 countdown
Highlighting some work being presented at this meeting NEXT WEEK by colleagues who are on this platform (say hi & comment on their work!)
#Rheumatology #MedSky 🧪
Highlighting some work being presented at this meeting NEXT WEEK by colleagues who are on this platform (say hi & comment on their work!)
#Rheumatology #MedSky 🧪
October 19, 2025 at 2:00 PM
#ACR25 countdown
Highlighting some work being presented at this meeting NEXT WEEK by colleagues who are on this platform (say hi & comment on their work!)
#Rheumatology #MedSky 🧪
Highlighting some work being presented at this meeting NEXT WEEK by colleagues who are on this platform (say hi & comment on their work!)
#Rheumatology #MedSky 🧪